New Urine Test for Prostate Cancer Enhances Diagnosis and Reduces Biopsies
University of Michigan researchers develop MPS2, a test that accurately identifies high-grade prostate cancer, minimizing invasive procedures.
- MPS2 targets 18 specific genes associated with aggressive prostate cancer, improving diagnostic accuracy.
- The test significantly reduces unnecessary biopsies, with up to 41% avoidance compared to traditional PSA testing.
- Developed from a decade of research, MPS2 builds on earlier tests by adding new biomarkers for better detection.
- The test is nearly 100% effective in ruling out low-grade, non-aggressive prostate cancers.
- MPS2 is now available commercially through LynxDx, offering a non-invasive option for at-risk patients.
UPI 
ScienceDaily 
Evening Standard 